Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,020
Completed, industry sponsors, Neurology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting130
- Completed1,020
1,020 trials
Showing 1 to 25, recently updated first.
- Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's DiseasePivotal-lookingCompleted
AriBio Co., Ltd.Industry
NCT03625622 · 210 participants · Start Apr 1, 2019 · Primary completion Dec 21, 2020
Drug: AR1001 10mg; Placebo and 1 more · For: Mild to Moderate Alzheimer's Disease
Sites: Banning, California; Sacramento, California; Santa Ana, California · 21 sites in all
- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of MigrainePivotal-lookingCompleted
TriGemX Bio, Inc.Industry
NCT06848075 · 431 participants · Start Mar 11, 2025 · Primary completion Aug 4, 2025
Drug: Elismetrep (K-304) 2 mg; Elismetrep (K-304) 5 mg and 3 more · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 66 sites in all
Mapi Pharma Ltd.Industry
NCT02212886 · 25 participants · Start Oct 2014 · Primary completion May 2017
Drug: GA Depot 80 mg; GA Depot 40 mg · For: Multiple Sclerosis
Sites: Ashkelon, Israel; Haifa, Israel; Tel Aviv, Israel
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04895722 · 302 participants · Start Jun 25, 2021 · Primary completion May 21, 2025
Drug: Pembrolizumab; Pembrolizumab/Quavonlimab and 3 more · For: Colorectal Cancer
Sites: Orange City, Florida; Athens, Georgia; Chicago, Illinois · 109 sites in all
- Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced DyskinesiaCompleted
Celon Pharma SAIndustry
NCT05297201 · 105 participants · Start Nov 2, 2021 · Primary completion Jan 13, 2025
Drug: CPL500036 - low dose; CPL500036 - high dose and 1 more · For: Parkinson Disease; Dyskinesia, Medication-Induced
Sites: Warsaw, Poland; Oświęcim, Poland; Cherkasy, Ukraine · 16 sites in all
Tiziana Life Sciences LTDIndustry
NCT06292923 · 54 participants · Start Nov 15, 2023 · Primary completion Sep 17, 2026
Drug: Foralumab · For: Secondary Progressive Multiple Sclerosis
Sites: North Haven, Connecticut; Baltimore, Maryland; Boston, Massachusetts · 8 sites in all
Lantheus Biosciences Ltd.Industry
NCT00750282 · 422 participants · Start Aug 2008 · Primary completion Nov 2010
Drug: Florbetaben (BAY94-9172) · For: Alzheimer Disease; Amyloid Beta-Protein
Sites: Sun City, Arizona; Stanford, California; New Haven, Connecticut · 23 sites in all
- ALS Phase II Study of NX210cCompleted
Axoltis PharmaIndustry
NCT06365216 · 83 participants · Start Oct 25, 2024 · Primary completion Dec 29, 2025
Drug: NX210c; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Brest, France; Caen, France; Marseille, France · 16 sites in all
- Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDPivotal-lookingCompleted
Bial R&D Investments, S.A.Industry
NCT05819359 · 273 participants · Start Mar 31, 2023 · Primary completion Apr 2, 2026
Drug: BIA 28-6156 10 mg; BIA 28-6156 60 mg and 1 more · For: Parkinson's Disease
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 95 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04704219 · 160 participants · Start Feb 23, 2021 · Primary completion Jan 27, 2025
Drug: Pembrolizumab; Lenvatinib · For: Renal Cell Carcinoma
Sites: Washington D.C., District of Columbia; Billings, Montana; Las Vegas, Nevada · 56 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04165083 · 100 participants · Start Jan 7, 2021 · Primary completion Oct 31, 2025
Drug: Pembrolizumab; MK-4830 and 1 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Duarte, California; San Francisco, California · 39 sites in all
NeuroTherapia, Inc.Industry
NCT07058688 · 48 participants · Start Mar 1, 2025 · Primary completion Feb 15, 2026
Drug: NTRX-07; Placebo · For: Alzheimer Disease; Mild Cognitive Impairment
Sites: Brno, Czechia; Prague, Czechia; Budapest, Hungary · 6 sites in all
Aadi Bioscience, Inc.Industry
NCT05103358 · 128 participants · Start Mar 10, 2022 · Primary completion Dec 23, 2024
Drug: nab-sirolimus · For: Tumor; Tumor, Solid; Metastasis and 18 more
Sites: Birmingham, Alabama; Mobile, Alabama; Goodyear, Arizona · 166 sites in all
- A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisPivotal-lookingCompleted
NCT06149559 · 14 participants · Start Jun 14, 2024 · Primary completion Oct 5, 2026
Drug: rozanolixizumab · For: Generalized Myasthenia Gravis
Sites: Bologna, Italy; Milan, Italy; Naples, Italy · 9 sites in all
- A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseasePivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT06881836 · 260 participants · Start Apr 24, 2025 · Primary completion Jul 31, 2026
Drug: ONO-2020; Placebo · For: Alzheimer Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Sun City, Arizona · 80 sites in all
Neurelis, Inc.Industry
NCT05076838 · 36 participants · Start Nov 8, 2021 · Primary completion Mar 11, 2025
Drug: Diazepam Nasal Spray [Valtoco] · For: Epilepsy
Sites: Gulf Breeze, Florida; Miami, Florida; Orlando, Florida · 13 sites in all
Shanghai WD Pharmaceutical Co., Ltd.Industry
NCT05036473 · 40 participants · Start Nov 25, 2021 · Primary completion Dec 28, 2022
Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets; Placebo · For: Parkinson Disease
Sites: Shanghai, China
AL-S PharmaIndustry
NCT05039099 · 73 participants · Start Sep 2, 2021 · Primary completion Aug 13, 2025
Drug: AP-101; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: La Jolla, California; Leuven, Belgium; Edmonton, Canada · 13 sites in all
IRulya Therapeutics Inc.Industry
NCT05163886 · 15 participants · Start Dec 23, 2021 · Primary completion Jan 11, 2023
Drug: LAM-002A · For: Amyotrophic Lateral Sclerosis; ALS
Sites: Iowa City, Iowa; Baltimore, Maryland; Boston, Massachusetts
NeuroPro Therapeutics, Inc.Industry
NCT06769659 · 14 participants · Start Mar 11, 2025 · Primary completion Aug 17, 2026
Drug: NPT 2042 · For: Epilepsy, Generalized; Epilepsy, Absence
Sites: Little Rock, Arkansas
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05007106 · 611 participants · Start Sep 16, 2021 · Primary completion Aug 5, 2025
Drug: Pembrolizumab/Vibostolimab Co-Formulation; Pembrolizumab and 10 more · For: Uterine Cervical Neoplasms; Endometrial Neoplasms; Squamous Cell Carcinoma of Head and Neck and 8 more
Sites: Anchorage, Alaska; Duarte, California; Orange, California · 73 sites in all
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626479 · 393 participants · Start Dec 16, 2020 · Primary completion Aug 10, 2026
Drug: Pembrolizumab; Favezelimab/Pembrolizumab and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 55 sites in all
- Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple SclerosisPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06083753 · 182 participants · Start Nov 6, 2023 · Primary completion Jul 14, 2025
Drug: PIPE-307 Dose A; PIPE-307 Dose B and 1 more · For: Relapsing Remitting Multiple Sclerosis
Sites: Phoenix, Arizona; Berkeley, California; Colorado Springs, Colorado · 21 sites in all
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626518 · 263 participants · Start Dec 17, 2020 · Primary completion Jul 23, 2026
Drug: Pembrolizumab; MK-4830 and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
Elixiron Immunotherapeutics Inc.Industry
NCT06745583 · 7 participants · Start Dec 16, 2024 · Primary completion Mar 6, 2026
Drug: EI-1071 tablet, oral · For: Mild, Moderate, or Severe Alzheimer's Disease
Sites: Taipei, Taiwan · 2 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.